A pregnant patient is taking Adderall (amphetamine/dextroamphetamine); should the medication be tapered or discontinued?

Management of Adderall During Pregnancy: Continue with Shared Decision-Making

Do not routinely discontinue or taper Adderall in pregnant patients if the medication is required for daily functioning—the consensus is that documented risks are very low and treatment should not be stopped when needed for maternal well-being 1.

Evidence-Based Approach

Primary Recommendation: Individualized Risk-Benefit Discussion

The 2024 American Journal of Obstetrics and Gynecology guidelines provide clear direction 1:

• If the patient requires Adderall for daily functioning: Continue the current well-tolerated, effective dose OR consider intermittent (as-needed) use to reduce total fetal exposure while maintaining maternal function
• If discontinuation won't severely impact functioning: Consider gradual taper before or early in pregnancy
• Alternative option: Switch to bupropion if co-occurring depression exists, though recognize it's less efficacious for ADHD than stimulants 1

Safety Profile of Amphetamines in Pregnancy

The evidence is largely reassuring 1:

Amphetamines (including Adderall) do NOT appear associated with:

• Major congenital malformations
• Cardiac malformations
• Significant adverse developmental outcomes

Possible small increased risks (but clinically debatable):

• Gastroschisis (aOR 3.0, but absolute risk remains tiny at 0.05% population prevalence, confounding likely) 1
• Preeclampsia (aRR 1.29)—small increase, other studies haven't replicated 1, 2
• Preterm birth if continued into second half of pregnancy (aRR 1.30)—small increase 1, 2

Critical context: These risks may be attributable to ADHD itself rather than medication, as untreated ADHD carries risks including spontaneous abortion and preterm birth 1.

The Risk of Discontinuation

Discontinuing stimulants during pregnancy leads to 1:

• Worse mental health outcomes
• Significant functional impairment in the pregnant person
• Potential negative impacts on fetus/baby from untreated maternal ADHD

This is a risk-risk analysis, not risk-benefit—both options carry risks 3.

Most Recent High-Quality Evidence

A 2025 population-based cohort study with meta-analysis found no increased risk of neurodevelopmental disorders in offspring exposed to ADHD medications in utero 4. For new users, methylphenidate appears most thoroughly studied, but for patients already stable on amphetamines, there's no compelling safety reason to switch 4.

Practical Management Algorithm

During Pregnancy:

1. Assess functional impairment: Can the patient safely manage pregnancy, work, driving, and daily activities without medication?

2. If medication is essential:

   • Continue current dose
   • OR implement intermittent dosing (take only on days when functioning demands are highest)
   • Engage in thorough informed consent discussion

3. Enhanced monitoring:

   • Blood pressure checks (preeclampsia risk)
   • Fetal growth surveillance
   • Maternal weight gain monitoring
   • Document shared decision-making 1

Breastfeeding Considerations:

The FDA label notes amphetamines are excreted in breast milk 5. However, guidelines recommend 1:

• Discuss breastfeeding safety with amphetamine derivatives
• Consider intermittent use and timing feeds/pumping to minimize infant exposure
• Monitor infant for irritability, insomnia, feeding difficulty 1
• Breastfeeding does not appear to adversely affect infants in therapeutic use 1

Common Pitfalls to Avoid

1. Reflexive discontinuation: Don't automatically stop medication upon pregnancy discovery—77% of patients discontinue during pregnancy 6, but this may not be optimal for all patients

2. Ignoring maternal morbidity: Untreated ADHD impairs driving safety, occupational function, and mental health 3—these are real risks to mother and pregnancy

3. Confusing illicit amphetamine data with therapeutic use: Much older literature examined illicit stimulant use; therapeutic ADHD treatment data is reassuring 1

4. Abrupt discontinuation: If tapering is chosen, do so gradually—stimulants can be stopped quickly due to rapid offset, but consider functional impact 1

Key Monitoring Parameters

• Maternal blood pressure (every visit)
• Fetal growth ultrasounds (consider serial growth scans)
• Maternal weight gain trajectory
• Infant development postpartum (weight gain, milestones) 1

The magnitude of documented medication risks is very low, and consensus supports continuing treatment when required for maternal daily functioning 1. The decision should prioritize maternal quality of life and functional capacity, as these directly impact pregnancy outcomes.